HealthBeacon : 2022 Interim Results Presentation

1

Investor Presentation

2022 Half Year Results

30 September 2022

Smart tools for managing medication

Overview &

highlights

2

Overview

Delivering an industry leading solution to a real, global problem at an accelerating pace

Leadership

The HealthBeacon© has built and launched the world's first FDA cleared Smart Sharps Technology that material impacts adherence to injectable therapy.

HealthBeacon has strengthened its position significantly as the world's leading digital therapeutics platform for patients managing medications in the home, signing transformational contracts with a number of the world's leading health systems, pharma companies

Momentum

Customer wins; New Partnerships; Key Appointments; Capacity Expansion; Product Development; increasing routes to market; and the signing of 7 international clients to its notable client base in 2022 will support the Company's Growth Trajectory

	>600k
	Injections
25 global clients	3 product & Tracker
service
(+7 in 2022 YTD)	launches

70+

employees

across key

markets

1 World's 1st FDA cleared Smart

+57%# Sharps Bin

increase in

revenue

100k Unit target for Q1 FY2024

25 Global pharma + large health system clients

26 Improvement in medical adherence % clinically evidenced

Up to

3

Accelerating growth driving progress

Significant traction underpinning 100k target; momentum built on pace of consistent leadership delivery

H2 2021

• NHSx approval received
• Medicare Remote Therapeutic Monitoring Codes published with addition of medication adherence devices
• Peer-reviewedpublication of 19% persistence increase
• Second US Specialty Pharmacy project launched
• €25m IPO completed in December 2021 (Gross Proceeds)
• +122% increase in units deployed in December 2021 (versus December 2020)

Q1 2022

• DTC Launch in partnership with Hamilton Beach
• Evernorth Specialty Pharmacy commercial contract signed
• Peer-reviewedpublication of 26% adherence increase
• 35k units ordered to fulfil near term demand
• EPA approval for HealthBeacon's Green Labs. Enables more sustainable processing of sharp bins & injection waste
• Patient Safety Software Platform Launched

Q2+ 2022

• Pivoted and modified processes quickly to resolve supply chain delay
• Continued expansion of client base to 25 currently, from 18 at the end of 2021
• Added to Evernorth's Digital Health Formulary, an industry-firstplatform of credible health apps validating the quality and effectiveness of our ICMS
• Two new products launched HB Smart Pills and HB Smart Scale further leaning into our existing channels and client base
• Commercial Partnership with the American Pharmacists Association (APhA)
• US launch of Green Labs.
• Commenced Trading on the OTCQX Market

Underpinning

100K target by

end of Q1

2024

4

Multiple routes to market delivering value

Unlocking the US opportunity through specialty pharmacy and payer support

1 Patient Support

Programmes

2	Direct to	3	Reimbursed Digital
Consumer ("DTC")	Therapeutic ("DTx")

Significant traction with Specialty Pharmacy organisations in the US

Currently working with 3 of the top 5 organisations

US and Canada Strategic Partnership announced with Hamilton Beach

Leverage relationship with retailers and brand

Public or private insurer payer compensates HealthBeacon for the provision of our Smart Sharps Bin

Currently trialling Medicare reimbursement in the US

Added to Evernorth's Digital Health Formulary. The world's leading digital therapeutics platform

Access to significant patient volumes on critical medications

Progress rollout throughout	Medicare now reimburse		*
retailers gaining access to
remote therapeutic
patients in the pharmacy	=	100k
monitoring devices
setting
Lean into retail pharmacy	Working with Clinicians to		units
enhance opportunity
organisations and pharmacists
Progress channel through
recommendation power
+	2023 and 2024 in the US
+

Real Time RX	Safe + Sustainable	Engagement	AI + Clinical
Monitoring	Disposal	+ Education	Support

*By Q1 2024

5